XOMA Corp: insider trades · United States · SEC (Form 4)

About XOMA Corp

XOMA Corp is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker XOMA. For French-speaking investors, it is best understood not as a traditional drug developer, but as a specialized biopharma royalty aggregator focused on acquiring, structuring, and managing intellectual-property-derived cash flows. The company is headquartered in Emeryville, California, United States, and has evolved toward a capital-light model centered on royalties, milestone payments, and other economic interests tied to biopharmaceutical programs and transactions. ([xoma.com](https://xoma.com/news/press-releases/?utm_source=openai)) XOMA’s history dates back to the earlier era of U.S. biotech, when the company was more directly engaged in therapeutic development. Over time, it has deliberately shifted away from the economics and uncertainty of internal R&D and toward a portfolio strategy that monetizes contract rights and future revenues. That repositioning gives XOMA a distinct investment profile: it still sits within healthcare and biotech, but its business model is closer to specialized intellectual-property finance than to a conventional clinical-stage biotech. ([investors.xoma.com](https://investors.xoma.com/sec-filings/annual-reports/content/0001104659-26-030872/xoma-20251231x10k.htm?TB_iframe=true&height=auto&preload=false&width=auto&utm_source=openai)) Today, the core of the business is built around three pillars: buying royalty streams and milestone rights, structuring transactions around biopharma assets, and actively managing a growing portfolio of contractual economic interests. XOMA often participates in acquisitions of development-stage or pre-commercial assets, then benefits from cash flows generated by partner companies. Recent examples include the acquisition of Generation Bio, the ongoing LAVA Therapeutics transaction, and the purchase of remaining mezagitamab royalty and milestone rights from BioInvent. In its March 2026 financial release, the company reported $50.5 million in cash receipts for full-year 2025, underlining the portfolio’s ability to generate meaningful incoming cash. ([xoma.com](https://xoma.com/news/press-releases/?utm_source=openai)) From a competitive standpoint, XOMA stands apart from typical biotech peers because it is not trying to win primarily through laboratory discovery or late-stage clinical execution. Instead, its edge lies in sourcing attractive royalty assets, structuring transactions effectively, and building a diversified exposure to multiple therapeutic programs. That model can reduce dependence on any single drug development outcome, although it still carries risk tied to counterparties, regulatory milestones, and commercial uptake by partners. In other words, XOMA is a biotech business, but with a financial-engineering overlay. ([investors.xoma.com](https://investors.xoma.com/news-events/press-releases/detail/488/xoma-royalty-reports-third-quarter-and-year-to-date-2025?utm_source=openai)) Geographically, the company remains anchored in the United States, with headquarters in California, while its royalty interests span partners and programs across multiple international biopharma markets. The most important recent corporate development for equity investors is the April 2026 announcement that Ligand Pharmaceuticals agreed to acquire XOMA Royalty, validating the strategic value of XOMA’s royalty portfolio within the public biotech ecosystem. For investors in Europe, XOMA is therefore an unusual NASDAQ healthcare name: a royalty-driven biotech platform with M&A optionality, recurring cash generation, and exposure to the broader commercialization cycle of global pharmaceutical assets. ([investors.xoma.com](https://investors.xoma.com/news-events/press-releases/detail/500/ligand-to-acquire-xoma-royalty-further-accelerating-profit?utm_source=openai))